1. Home
  2. UHT vs BWAY Comparison

UHT vs BWAY Comparison

Compare UHT & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UHT

Universal Health Realty Income Trust

HOLD

Current Price

$40.05

Market Cap

552.2M

Sector

Real Estate

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$12.82

Market Cap

450.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UHT
BWAY
Founded
1986
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
552.2M
450.8M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
UHT
BWAY
Price
$40.05
$12.82
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.25
AVG Volume (30 Days)
52.7K
169.7K
Earning Date
04-27-2026
03-11-2026
Dividend Yield
7.49%
N/A
EPS Growth
N/A
N/A
EPS
1.27
N/A
Revenue
$99,190,000.00
N/A
Revenue This Year
$2.12
$301.23
Revenue Next Year
$2.94
$24.33
P/E Ratio
$31.34
$81.98
Revenue Growth
0.18
N/A
52 Week Low
$35.26
$7.84
52 Week High
$44.70
$26.63

Technical Indicators

Market Signals
Indicator
UHT
BWAY
Relative Strength Index (RSI) 32.08 29.70
Support Level $38.72 $11.55
Resistance Level $41.64 $13.63
Average True Range (ATR) 1.08 0.72
MACD -0.42 0.19
Stochastic Oscillator 11.22 17.62

Price Performance

Historical Comparison
UHT
BWAY

About UHT Universal Health Realty Income Trust

Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: